Compare Ascendis Pharma A/S (ASND) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Rush Street Interactive Inc — how do they compare? Ascendis Pharma A/S trades at $265.33 (market cap $17.74B), while Rush Street Interactive Inc trades at $34.25 (market cap $3.44B). The key difference: Ascendis Pharma A/S is far larger — about 5.2× Rush Street Interactive Inc's market cap, and Rush Street Interactive Inc is trading nearer its 52-week high, Ascendis Pharma A/S nearer its low. Which is the better fit depends on your goals.
| ASND | RSI | |
|---|---|---|
Market Cap | $17.74B | $3.44B |
Sector | Health | Technology |
52-Week High | $277.18 | $33.40 |
52-Week Low | $163.32 | $14.51 |
Enterprise Value | $18.11B | $3.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
RSI stock trades at $33.40, up 2.36% today, with strong technical momentum and a bullish moving average signal. The company reported Q1 2026 EPS of $0.14, beating expectations, with revenue growth projected to $1.2B in 2026. Positive sentiment is driven by a 76.9% analyst buy rating and a $100M share repurchase program announced on May 5, 2026.
Outlook remains positive given earnings beats and growth initiatives, but high P/E of 98.24 signals valuation risk. Key risks include competitive pressures and reliance on sports betting trends. The consensus price target is $29.44, suggesting limited upside from current levels amid elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
